Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: Analysis of drug interactions and efficacies

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 242-250

  Walzer, Peter D ^a,b   Runck, Jennifer ^b   Orr, Sally ^b   Foy, Jilanna ^b   Steele, Paul ^b   White, Michael ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; ATOVAQUONE; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; MEVINOLIN; RIFABUTIN;

AIDS RELATED COMPLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; FEMALE; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS;

EID: 0031053882     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.242     Document Type: Article

References (40)

1. Alder, J., M. Mitten, N. Shipkowitz, L. Hernandez, Y. Hui, K. Marsh, and J. Clement. 1994. Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole. J. Antimicrob. Chemother. 33:253-263.
2. Araujo, F. G., T. Slifer, and J. S. Remington. 1994. Rifabutin is active in murine models of toxoplasmosis. Antimicrob. Agents Chemother. 38:570-575.
3. Bartlett, M., S. Queener, M. Shaw, J. Richardson, and J. Smith. 1994. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob. Agents Chemother. 38:1859-1861.
4. Black, J. R., J. Feinberg, R. F. Murphy, R. J. Fass, J. Carey, and F. R. Sattler. 1991. Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii in patients with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 10:204-207.
5. Brun-Pascaue, M., F. Chau, L. Garry, D. Jacobus, F. Derouin, and M. Girard. 1996. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob. Agents Chemother. 40:2067-2070.
6. Centers for Disease Control and Prevention. 1995. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. Morbid. Mortal. Weekly Rep. 44:1-34.
7. Clarkson, A., S. Muhamed, and R. Grady. 1990. Deferoxamine and eflornithine (DL-α-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 34:1833-1835.
8. Comley, J. C. W., and A. M. Sterling. 1995. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob. Agents Chemother. 39:806-811.
9. Crampton, S., J. C. Craft, G. Notaro, and D. Henry. 1996. Prevention of Pneumocystis carinii pneumonia in AIDS patients by clarithromycin prophylaxis for Mycobacterium avium complex (MAC). In Abstracts of the Third International Conference on Macrolides, Azalides, and Streptogramins.
10. Frenkel, J. K., J. T. Good, and J. A. Schultz. 1966. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab. Invest. 15:1559-1577.
11. Gonzalez-Ruiz, A., S. Haworth, A. O'Neil, and D. Warhurst. 1991. Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model. J. Infect. 22:143-152.
12. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
13. Guay, D. R. P., D. R. Patterson, N. Seipman, and J. C. Craft. 1993. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Safety 18:350-364.
14. Guo-Zhong, C., L. Foster, and J. Bennett. 1990. Antischistosomal action of mevinolin: evidence that 3-hydroxy-methylglutaryl-coenzyme a reductase activity in Schistosoma mansoni is vital for parasite survival. Arch Pharmacol. 342:477-482.
15. Hughes, W. T., J. Killmar, and H. Oz. 1994. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model. J. Infect. Dis. 170:906-911.
16. Hughes, W. T., and B. L. Smith. 1984. Efficacy of diaminodiphenyl-sulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother. 26:436-440.
17. Kaneshiro, E., J. Ellis, H. Zhou, H. Rudney, A. Gupta, K. Jayasimhulu, K. Setchell, and D. Beach. 1994. Isoprenoid metabolism in Pneumocystis carinii. J. Eukaryot. Microbiol. 41(Suppl.):93.
18. Kaneshiro, E. S., J. E. Ellis, K. Jayasimhulu, and D. E. Beach. 1994. Evidence of "metabolic sterols" in Pneumocystis: identification and initial characterization of Pneumocystis carinii sterols. J. Eukaryot. Microbiol. 41:78-85.
19. Kim, C. K., J. M. Foy, M. T. Cushion, D. Stanforth, M. J. Linke, H. L. Hendrix, and P. D. Walzer. 1987. Comparison of histologic and quantitative techniques in the evaluation of experimental Pneumocystis carinii. Antimicrob. Agents Chemother. 31:197-201.
20. Kluge, R., D. Spaulding, and A. Spain. 1978. Combination of pentamidine and trimethoprim-sulfamethoxazole in the therapy of Pneumocystis carinii pneumonia in rats. Antimicrob. Agents Chemother. 13:975-978.
21. Lee, B., I. Medina, N. Benowitz, P. Jacob, C. Wofsy, and J. Mills. 1989. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug reactions. Ann. Intern. Med. 110:606-611.
22. Lorenz, R. T., and L. Parks. 1990. Effects of lovastatin (Mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob. Agents and Chemother. 34:1660-1665.
23. Masur, H. 1992. Prevention and treatment of Pneumocystis carinii pneumonia. N. Engl. J. Med. 327:1853-1860.
24. 0 analog L-733,560. Antimicrob. Agents. Chemother. 38:2258-2265.
25. Queener, S. F., M. S. Bartlett, J. D. Richardson, M. M. Durkin, M. M. Jay, and J. W. Smith. 1988. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. 32:807-813.
26. Romand, S., M. Pudney, and F. Derouin. 1993. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob. Agents Chemother. 37:2371-2378.
27. SAS Institute, Inc. 1990. SAS/STAT user's guide, version 6, vol. 2, p. 948-949. SAS Institute, Inc., Cary, N.C.
28. Schmatz, D. 1994. The use of β-1,3-glucan synthesis inhibitors for the treatment and prevention of Pneumocystis carinii pneumonia, p. 615-632. In P. D. Walzer (ed.), Pneumocystis carinii. Marcel Dekker, Inc., New York, N.Y.
29. Smith, T. J., S. F. Queener, M. S. Bartlett, M. M. Shaw, and J. W. Smith. 1994. In Abstracts of the American Society of Tropical Medicine and Hygiene, 43rd Annual Meeting.
30. Sturgill, M. G., and R. P. Rapp. 1992. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann. Pharmacother. 26:1099-1108.
31. Tidwell, R., S. Jones, N. Naiman, L. Berger, W. Brake, C. Dykstra, and J. Hall. 1993. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob. Agents and Chemother. 37:1713-1716.
32. Urbina, J. A., K. Lazardi, E. Marchan, G. Visbal, T. Aguirre, M. Piras, R. Piras, R. A. Maldonado, G. Payares, and W. De Souza. 1993. Mevinolin (Lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Tiypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents and Chemother. 37:580-591.
33. Wakefield, A. E. 1995. Re-examination of epidemiological concepts, p. 431-448. In F. Sattler and P. D. Walzer (ed.), Pneumocystis carinii. Baillere Tindall Ltd., London, United Kingdom.
34. Walpole, R. E., and R. H. Myers. 1989. Probability and statistics for engineers and scientists, p. 535-571. 592-601. Macmillan, Inc., New York, N.Y.
35. Walzer, P. D., J. Foy, J. Runck, P. Steele, M. White, R. S. Klein, B. A. Otter, and R. J. Sundberg. 1994. Guanylhydrazones in treatment of Pneumocystis carinii pneumonia in immunosuppressed rats. Antimicrob. Agents Chemother. 38:2572-2576.
36. Walzer, P. D., J. Foy, P. Steele, and M. White. 1993. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone in the therapy of experimental pneumocystosis. Antimicrob. Agents Chemother. 37:1436-1443.
37. Walzer, P. D., J. Foy, P. E. Steele, C. K. Kim, M. White, R. Klein, B. Otter, and C. Allegra. 1992. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 36:1935-1942.
38. Walzer, P. D., J. Foy, P. Steele, and M. White. 1992. Treatment of experimental pneumocystosis: review of seven years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob. Agents Chemother. 36:1943-1950.
39. Walzer, P. D., C. K. Kim, J. M. Foy, M. J. Linke, and M. T. Cushion. 1988. Inhibitors of folic acid synthesis in the treatment of experimental Pneumo cystis carinii pneumonia. Antimicrob. Agents Chemother. 32:96-103.
40. Yasuoka, A., S. Oka, K. Komuro, H. Shimizu, K. Kitada, Y. Nakamura, S. Shibahara, T. Takeuchi, S. Kondo, K. Shimada, and S. Kimura. 1995. Successful treatment of Pneumocystis carinii pneumonia in mice with benanomicin A (ME1451). Antimicrob. Agents Chemother. 39:720-724.